Literature DB >> 35713788

Inhibitory Effects of Cold Atmospheric Plasma on Inflammation and Tumor-Like Feature of Fibroblast-Like Synoviocytes from Patients with Rheumatoid Arthritis.

Fatemeh Faramarzi1, Parisa Zafari1, Mina Alimohammadi2, Monireh Golpour3, Salman Ghaffari4, Alireza Rafiei5.   

Abstract

Rheumatoid arthritis (RA) is a chronic, debilitating systemic disease characterized by chronic inflammation and progressive joint destruction. Fibroblast-like synoviocytes (FLSs) are one of the most important players in the pathophysiology of RA, acting like tumor cells and secreting inflammatory cytokines. Previous research has shown that cold atmospheric plasma (CAP) inhibits cancer cells and may have anti-inflammatory properties. This study examined the effects of argon plasma jet-produced CAP on the suppression of invasion and inflammation caused by cultured RA-FLS. The findings revealed that CAP reduced cell viability and elevated the percentage of apoptotic RA-FLS by producing reactive oxygen species. Carboxyfluorescein diacetate succinimidyl ester (CFSE) staining confirmed that CAP could decrease the proliferation of RA-FLS. Furthermore, CAP effectively reduced the production of inflammatory factors (e.g., NF-κB and IL-6) as well as destructive factors like receptor activator of nuclear factor kappa-B ligand (RANKL) and matrix metalloproteinases-3 (MMP-3). These data suggest that CAP could be a promising treatment for slowing the progression of RA by reducing tumor-like features and inflammation in RA-FLS.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  MMP-3; RANKL.; apoptosis; cold atmospheric plasma; fibroblast-like synoviocytes; inflammation

Year:  2022        PMID: 35713788     DOI: 10.1007/s10753-022-01703-3

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  55 in total

Review 1.  The pathogenesis of rheumatoid arthritis.

Authors:  Iain B McInnes; Georg Schett
Journal:  N Engl J Med       Date:  2011-12-08       Impact factor: 91.245

Review 2.  Osteoclasts, rheumatoid arthritis, and osteoimmunology.

Authors:  Kojiro Sato; Hiroshi Takayanagi
Journal:  Curr Opin Rheumatol       Date:  2006-07       Impact factor: 5.006

3.  Ultrastructure of synovial membrane in rheumatoid arthritis.

Authors:  F N Ghadially; S Roy
Journal:  Ann Rheum Dis       Date:  1967-09       Impact factor: 19.103

Review 4.  Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis.

Authors:  Beatrix Bartok; Gary S Firestein
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

5.  Synovial fibroblast hyperplasia in rheumatoid arthritis: clinicopathologic correlations and partial reversal by anti-tumor necrosis factor therapy.

Authors:  Elena Izquierdo; Juan D Cañete; Raquel Celis; Manuel J Del Rey; Alicia Usategui; Sara Marsal; Raimon Sanmartí; Gabriel Criado; José L Pablos
Journal:  Arthritis Rheum       Date:  2011-09

Review 6.  Rheumatologic and autoimmune manifestations of primary immunodeficiency disorders.

Authors:  Ramona Goyal; Ariel C Bulua; Nikolay P Nikolov; Pamela L Schwartzberg; Richard M Siegel
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

7.  Quantitation of human synovial mast cells in rheumatoid arthritis and other rheumatic diseases.

Authors:  H P Godfrey; C Ilardi; W Engber; F M Graziano
Journal:  Arthritis Rheum       Date:  1984-08

Review 8.  The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis.

Authors:  Erika H Noss; Michael B Brenner
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

9.  The descriptive epidemiology of rheumatoid arthritis in Catalonia: a retrospective study using routinely collected data.

Authors:  F Fina-Aviles; M Medina-Peralta; L Mendez-Boo; E Hermosilla; J M Elorza; M Garcia-Gil; R Ramos; B Bolibar; M K Javaid; C J Edwards; C Cooper; N K Arden; D Prieto-Alhambra
Journal:  Clin Rheumatol       Date:  2014-10-26       Impact factor: 2.980

Review 10.  The fibroblast as a therapeutic target in rheumatoid arthritis.

Authors:  Andrew Filer
Journal:  Curr Opin Pharmacol       Date:  2013-04-03       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.